SLC5A2 and autosomal dominant polycystic kidney disease: However, a recent retrospective cohort study of 348 patients with ADPKD (93% male; mean age ± SD, 68 ± 11 years) demonstrated that those who initiated SGLT2 inhibitors experienced a slower rate of eGFR decline, particularly beyond the initial 3 months of therapy.